{"id":"razoxane","rwe":[{"pmid":"41581093","year":"2026","title":"Use of Razoxane as a radiosensitizer for the treatment of soft tissue sarcomas.","finding":"","journal":"Expert review of anticancer therapy","studyType":"Clinical Study"},{"pmid":"29140426","year":"2018","title":"Development and Validation of Stereo Selective Method for the Separation of Razoxane Enantiomers in Hydrophilic Interaction Chromatography.","finding":"","journal":"Journal of chromatographic science","studyType":"Clinical Study"},{"pmid":"26918678","year":"2016","title":"PAK1-cofilin phosphorylation mediates human lung adenocarcinoma cells migration induced by apelin-13.","finding":"","journal":"Clinical and experimental pharmacology & physiology","studyType":"Clinical Study"},{"pmid":"21235436","year":"2010","title":"Cell biological manifestations of bisdioxopiperazines treatment of human tumor cell lines in culture.","finding":"","journal":"Anti-cancer agents in medicinal chemistry","studyType":"Clinical Study"},{"pmid":"20950258","year":"2010","title":"Antimetastatic activities and mechanisms of bisdioxopiperazine compounds.","finding":"","journal":"Anti-cancer agents in medicinal chemistry","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Doxorubicin Induced Cardiomyopathy","category":"indication"},{"label":"Extravasation Injury from Anthracycline Injection","category":"indication"},{"label":"Antimitotic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"}],"phase":"phase_2","safety":{"contraindications":["Bone marrow depression","Impaired renal function disorder"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"razoxin","offLabel":[],"synonyms":["razoxane mesylate","razoxane","razoxin","tepirone","troxozone"],"timeline":[],"approvals":[],"brandName":"Razoxin","ecosystem":[{"indication":"Doxorubicin Induced Cardiomyopathy","otherDrugs":[{"name":"dexrazoxane","slug":"dexrazoxane","company":"Pharmacia And Upjohn"}],"globalPrevalence":null},{"indication":"Extravasation Injury from Anthracycline Injection","otherDrugs":[{"name":"dexrazoxane","slug":"dexrazoxane","company":"Pharmacia And Upjohn"}],"globalPrevalence":null}],"mechanism":{"modality":"Small Molecule","explanation":"Think of Razoxin like a magnet that attaches to iron and prevents it from causing harm. When anthracycline chemotherapy agents are used, they can release iron that damages the heart. Razoxin helps to bind to this iron and prevent it from causing damage.","oneSentence":"Razoxin works by chelating iron and preventing the formation of free radicals that damage heart tissue.","technicalDetail":"Razoxin acts as a metal chelator, specifically targeting iron and preventing the formation of reactive oxygen species (ROS) that contribute to cardiotoxicity."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4031","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=RAZOXANE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=RAZOXANE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:30:59.993380","biosimilars":[],"competitors":[],"genericName":"razoxane","indications":{"approved":[{"name":"Doxorubicin Induced Cardiomyopathy","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Extravasation Injury from Anthracycline Injection","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00980460","phase":"PHASE3","title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":["PRETEXT I Hepatoblastoma","PRETEXT II Hepatoblastoma","PRETEXT III Hepatoblastoma","PRETEXT IV Hepatoblastoma"],"enrollment":236,"completionDate":"2026-03-19"},{"nctId":"NCT05292664","phase":"PHASE1","title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"Andrew E. Place, MD","startDate":"2023-03-29","conditions":["Myelodysplastic Syndromes, de Novo","Myelodysplastic Syndromes, Secondary","Myelodysplastic Syndromes, Previously Treated","Treatment-Related Acute Myeloid Leukemia","Therapy-Related Myelodysplastic Syndrome","Acute Lymphoblastic Leukemia, in Relapse","Acute Lymphoblastic Leukemia With Failed Remission","Lymphoblastic Lymphoma, in Relapse","Lymphoblastic Lymphoma, Refractory","Acute Leukemia of Ambiguous Lineage in Relapse","Acute Leukemia of Ambiguous Lineage"],"enrollment":30,"completionDate":"2030-07-02"},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":["Ganglioneuroblastoma","Ganglioneuroblastoma, Nodular","Neuroblastoma"],"enrollment":750,"completionDate":"2030-09-30"},{"nctId":"NCT06647953","phase":"PHASE3","title":"Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-03-21","conditions":["Pleuropulmonary Blastoma"],"enrollment":110,"completionDate":"2029-03-31"},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":["Acute Myeloid Leukemia"],"enrollment":1186,"completionDate":"2029-06-30"},{"nctId":"NCT03755804","phase":"PHASE2","title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-12-12","conditions":["Hodgkin Lymphoma"],"enrollment":232,"completionDate":"2028-07-01"},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia","Mixed Phenotype Acute Leukemia","T Acute Lymphoblastic Leukemia"],"enrollment":475,"completionDate":"2027-09-30"},{"nctId":"NCT00400946","phase":"PHASE3","title":"05-001: Treatment of Acute Lymphoblastic Leukemia in Children","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2005-04","conditions":["Drug/Agent Toxicity by Tissue/Organ","Leukemia"],"enrollment":800,"completionDate":"2019-06"},{"nctId":"NCT07125183","phase":"PHASE2","title":"Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-12","conditions":["Sarcoma"],"enrollment":20,"completionDate":"2029-12"},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndromes"],"enrollment":206,"completionDate":"2027-06"},{"nctId":"NCT01231906","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2010-11-24","conditions":["Localized Extraskeletal Ewing Sarcoma","Peripheral Primitive Neuroectodermal Tumor of Bone","Peripheral Primitive Neuroectodermal Tumor of Soft Tissues"],"enrollment":642,"completionDate":"2025-12-31"},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":["Acute Lymphoblastic Leukemia, Pediatric"],"enrollment":560,"completionDate":"2034-11"},{"nctId":"NCT06220032","phase":"PHASE3","title":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2024-08-15","conditions":["DLBCL - Diffuse Large B Cell Lymphoma"],"enrollment":324,"completionDate":"2028-12-15"},{"nctId":"NCT01871766","phase":"PHASE2","title":"Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-04","conditions":["Rhabdomyosarcoma"],"enrollment":115,"completionDate":"2030-06"},{"nctId":"NCT03589729","phase":"PHASE2","title":"Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-09-19","conditions":["Acute Myeloid Leukemia","Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Blasts 10 Percent or More of Bone Marrow Nucleated Cells","High Risk Myelodysplastic Syndrome","Myeloid Sarcoma","Myeloproliferative Neoplasm","Philadelphia Chromosome Positive"],"enrollment":100,"completionDate":"2027-12-31"},{"nctId":"NCT01864109","phase":"PHASE2","title":"Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-05","conditions":["Newly Diagnosed Ewing Sarcoma"],"enrollment":83,"completionDate":"2027-05"},{"nctId":"NCT00077285","phase":"PHASE2","title":"Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-10","conditions":["Sarcoma"],"enrollment":65,"completionDate":"2026-10"},{"nctId":"NCT03786783","phase":"PHASE2","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-04","conditions":["Ganglioneuroblastoma","High Risk Neuroblastoma"],"enrollment":42,"completionDate":"2026-09-19"},{"nctId":"NCT06262438","phase":"PHASE2","title":"CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2024-02-06","conditions":["Acute Myeloid Leukemia in Children"],"enrollment":60,"completionDate":"2032-06"},{"nctId":"NCT05858710","phase":"PHASE1","title":"Study of DPPG2-TSL-DOX Combined With Hyperthermia in Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Thermosome GmbH","startDate":"2023-04-19","conditions":["Sarcoma, Soft Tissue"],"enrollment":8,"completionDate":"2025-05-28"},{"nctId":"NCT03930680","phase":"PHASE1","title":"Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2021-09-14","conditions":["Degradation of Top2b and Top2a in Human by Dexrazoxane","Time Course and Degradation of Top2b in Human by Dexrazoxane","Effects of Dexrazoxane on Healthy Human"],"enrollment":25,"completionDate":"2025-06-11"},{"nctId":"NCT01790152","phase":"","title":"Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2014-03-05","conditions":["Hodgkin Lymphoma in Remission","Leukemia in Remission","Lymphoblastic Lymphoma","Osteosarcoma","Recurrent Leukemia","Recurrent Lymphoma","Recurrent Malignant Neoplasm"],"enrollment":420,"completionDate":"2025-12-31"},{"nctId":"NCT04478292","phase":"PHASE3","title":"A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy","status":"RECRUITING","sponsor":"Shanghai Children's Medical Center","startDate":"2021-03-01","conditions":["Hepatoblastoma"],"enrollment":330,"completionDate":"2027-09-30"},{"nctId":"NCT04757337","phase":"PHASE3","title":"Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2021-06-18","conditions":["Advanced Soft-tissue Sarcoma","Metastatic Soft-tissue Sarcoma"],"enrollment":214,"completionDate":"2026-04"},{"nctId":"NCT01523977","phase":"PHASE1","title":"Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2011-11","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":22,"completionDate":"2018-11"},{"nctId":"NCT01606878","phase":"PHASE1","title":"Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2013-04-29","conditions":["Childhood Solid Neoplasm","Recurrent Childhood Anaplastic Large Cell Lymphoma","Recurrent Neuroblastoma"],"enrollment":46,"completionDate":"2018-12-31"},{"nctId":"NCT02584309","phase":"PHASE2","title":"Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-02-22","conditions":["Sarcoma, Soft Tissue","Soft Tissue Sarcoma","Undifferentiated Pleomorphic Sarcoma","Leiomyosarcoma","Liposarcoma","Synovial Sarcoma","Myxofibrosarcoma","Angiosarcoma","Fibrosarcoma","Malignant Peripheral Nerve Sheath Tumor","Epithelioid Sarcoma"],"enrollment":73,"completionDate":"2022-07-17"},{"nctId":"NCT04997291","phase":"PHASE1","title":"Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery","status":"UNKNOWN","sponsor":"University of Texas at Austin","startDate":"2021-04-09","conditions":["Heart Defects, Congenital"],"enrollment":12,"completionDate":"2022-01"},{"nctId":"NCT03698227","phase":"PHASE2","title":"OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients","status":"TERMINATED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2018-11-12","conditions":["Advanced Soft Tissue Sarcoma"],"enrollment":2,"completionDate":"2020-06-25"},{"nctId":"NCT02786719","phase":"NA","title":"High-Risk Neuroblastoma Chemotherapy Without G-CSF","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2016-06","conditions":["Neuroblastoma"],"enrollment":13,"completionDate":"2019-02-05"},{"nctId":"NCT00038142","phase":"PHASE2","title":"Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"1997-11","conditions":["Ewing's Sarcoma"],"enrollment":46,"completionDate":"2016-03"},{"nctId":"NCT00928200","phase":"PHASE1","title":"Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2009-04-13","conditions":["Relapsed Acute Lymphoblastic Leukemia","Allergy to PEG e.Coli Asparaginase","Allergy to Native e.Coli Asparaginase"],"enrollment":1,"completionDate":"2010-06-04"},{"nctId":"NCT01696669","phase":"PHASE2","title":"Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults","status":"COMPLETED","sponsor":"Grupo Espanol de Investigacion en Sarcomas","startDate":"2010-03-30","conditions":["Ewing's Sarcoma"],"enrollment":43,"completionDate":"2018-01-18"},{"nctId":"NCT02519335","phase":"PHASE1","title":"Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation","status":"TERMINATED","sponsor":"Medical City Children's Hospital","startDate":"2014-09","conditions":["Heart Defects, Congenital"],"enrollment":12,"completionDate":"2017-03"},{"nctId":"NCT02953184","phase":"PHASE2","title":"Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Jilin University","startDate":"2016-11","conditions":["Antineoplastic Combined Chemotherapy Protocols"],"enrollment":160,"completionDate":"2020-11"},{"nctId":"NCT00098839","phase":"PHASE1,PHASE2","title":"Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-02","conditions":["Recurrent Childhood Acute Lymphoblastic Leukemia"],"enrollment":134,"completionDate":"2011-04"},{"nctId":"NCT00581360","phase":"PHASE2","title":"Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2007-11","conditions":["Adenoid Cystic Carcinoma"],"enrollment":10,"completionDate":"2011-06"},{"nctId":"NCT00084838","phase":"PHASE2","title":"Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2003-02","conditions":["Central Nervous System Tumor, Pediatric"],"enrollment":25,"completionDate":"2013-03"},{"nctId":"NCT00548561","phase":"PHASE2,PHASE3","title":"Efficacy of TopotectTM (Dexrazoxane) for Accidental Extravasation of Anthracyclines","status":"COMPLETED","sponsor":"Valerio Therapeutics","startDate":"2001-06","conditions":["Anthracycline Extravasation"],"enrollment":23,"completionDate":"2003-07"},{"nctId":"NCT00548704","phase":"PHASE2,PHASE3","title":"A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines","status":"COMPLETED","sponsor":"Valerio Therapeutics","startDate":"2002-04","conditions":["Extravasation"],"enrollment":57,"completionDate":"2005-08"},{"nctId":"NCT00550901","phase":"PHASE1","title":"Dexrazoxane and Cisplatin in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2001-02","conditions":["Unspecified Adult Solid Tumor, Protocol Specific"],"enrollment":25,"completionDate":"2007-07"},{"nctId":"NCT00019864","phase":"PHASE2","title":"Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-03","conditions":["Cardiac Toxicity","Sarcoma"],"enrollment":100,"completionDate":"2011-10"},{"nctId":"NCT01596088","phase":"PHASE1,PHASE2","title":"A Phase I/II Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents","status":"COMPLETED","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"","conditions":["Extravasations of Anthracycline Anti-cancer Agents"],"enrollment":2,"completionDate":""},{"nctId":"NCT01627938","phase":"PHASE2","title":"Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination","status":"UNKNOWN","sponsor":"PD Dr. Andrew Chan","startDate":"2012-04","conditions":["Multiple Sclerosis"],"enrollment":50,"completionDate":"2016-04"},{"nctId":"NCT00673179","phase":"NA","title":"Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-05","conditions":["Osteosarcoma"],"enrollment":7,"completionDate":"2010-11"},{"nctId":"NCT00544778","phase":"PHASE2","title":"Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2001-08","conditions":["Sarcoma"],"enrollment":7,"completionDate":""},{"nctId":"NCT00003937","phase":"PHASE3","title":"Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1999-09","conditions":["Cardiac Toxicity","Sarcoma"],"enrollment":253,"completionDate":"2008-06"},{"nctId":"NCT00005578","phase":"PHASE3","title":"Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1997-03","conditions":["Cardiac Toxicity","Lymphoma"],"enrollment":219,"completionDate":"2008-06"},{"nctId":"NCT00742924","phase":"PHASE1","title":"Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-08","conditions":["Sarcoma"],"enrollment":24,"completionDate":""},{"nctId":"NCT00933985","phase":"PHASE1","title":"Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-06","conditions":["Acute Leukemias of Ambiguous Lineage","Acute Undifferentiated Leukemia","Angioimmunoblastic T-cell Lymphoma","Blastic Phase Chronic Myelogenous Leukemia","Childhood Burkitt Lymphoma","Childhood Chronic Myelogenous Leukemia","Childhood Diffuse Large Cell Lymphoma","Childhood Immunoblastic Large Cell Lymphoma","Childhood Nasal Type Extranodal NK/T-cell Lymphoma","Cutaneous B-cell Non-Hodgkin Lymphoma","Hepatosplenic T-cell Lymphoma","Intraocular Lymphoma","Noncutaneous Extranodal Lymphoma","Peripheral T-cell Lymphoma","Recurrent Childhood Acute Lymphoblastic Leukemia","Recurrent Childhood Acute Myeloid Leukemia","Recurrent Childhood Anaplastic Large Cell Lymphoma","Recurrent Childhood Grade III Lymphomatoid Granulomatosis","Recurrent Childhood Large Cell Lymphoma","Recurrent Childhood Lymphoblastic Lymphoma","Recurrent Childhood Small Noncleaved Cell Lymphoma","Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma","Recurrent Mycosis Fungoides/Sezary Syndrome","Recurrent/Refractory Childhood Hodgkin Lymphoma","Refractory Chronic Lymphocytic Leukemia","Refractory Hairy Cell Leukemia","Relapsing Chronic Myelogenous Leukemia","Small Intestine Lymphoma","Unspecified Childhood Solid Tumor, Protocol Specific"],"enrollment":22,"completionDate":"2013-04"},{"nctId":"NCT01258634","phase":"PHASE1","title":"A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2010-07","conditions":["Osteosarcoma","Lung Metastases"],"enrollment":2,"completionDate":"2011-11"},{"nctId":"NCT00002827","phase":"PHASE3","title":"Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-10","conditions":["Cardiac Toxicity","Lymphoma"],"enrollment":294,"completionDate":"2008-06"},{"nctId":"NCT00334867","phase":"PHASE3","title":"Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma","status":"WITHDRAWN","sponsor":"Children's Oncology Group","startDate":"2005-12","conditions":["Sarcoma"],"enrollment":0,"completionDate":""},{"nctId":"NCT00003667","phase":"PHASE2","title":"Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1998-09","conditions":["Sarcoma"],"enrollment":0,"completionDate":"2000-08"},{"nctId":"NCT01230983","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1996-06","conditions":["Cardiac Toxicity","Leukemia","Lymphoma"],"enrollment":573,"completionDate":"2004-10"},{"nctId":"NCT00165178","phase":"PHASE3","title":"Treatment of Acute Lymphoblastic Leukemia in Children","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2000-09","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":498,"completionDate":"2011-05"},{"nctId":"NCT00410488","phase":"NA","title":"Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-12","conditions":["Sarcoma","Nausea","Vomiting"],"enrollment":51,"completionDate":"2011-06"},{"nctId":"NCT00039481","phase":"PHASE1","title":"Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-11","conditions":["Cardiac Toxicity","Unspecified Childhood Solid Tumor, Protocol Specific"],"enrollment":15,"completionDate":""},{"nctId":"NCT00016276","phase":"PHASE3","title":"Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-05","conditions":["Cardiac Toxicity","Inflammatory Breast Cancer","Stage IIIA Breast Cancer","Stage IIIB Breast Cancer","Stage IV Breast Cancer"],"enrollment":396,"completionDate":""},{"nctId":"NCT00955890","phase":"PHASE2","title":"Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer","status":"TERMINATED","sponsor":"Fudan University","startDate":"2009-06","conditions":["Breast Cancer"],"enrollment":12,"completionDate":"2012-02"},{"nctId":"NCT00001335","phase":"PHASE2","title":"New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1993-04","conditions":["Ewing's Sarcoma","Neuroblastoma","Rhabdomyosarcoma"],"enrollment":90,"completionDate":"2002-01"},{"nctId":"NCT00165087","phase":"PHASE3","title":"Treatment of Childhood Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"1996-01","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":491,"completionDate":"2006-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000006134","NDDF":"004030","UNII":"5AR83PR647","CHEBI":"CHEBI:50225","INN_ID":"3675","RXNORM":"196454","UMLSCUI":"C0034738","ChEMBL_ID":"CHEMBL444186","KEGG_DRUG":"D08471","PUBCHEM_CID":"30623","SNOMEDCT_US":"387518009","MESH_DESCRIPTOR_UI":"D011929"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":154,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jan 29","pmid":"41581093","title":"Use of Razoxane as a radiosensitizer for the treatment of soft tissue sarcomas.","journal":"Expert review of anticancer therapy"},{"date":"2018 Feb 1","pmid":"29140426","title":"Development and Validation of Stereo Selective Method for the Separation of Razoxane Enantiomers in Hydrophilic Interaction Chromatography.","journal":"Journal of chromatographic science"},{"date":"2016 May","pmid":"26918678","title":"PAK1-cofilin phosphorylation mediates human lung adenocarcinoma cells migration induced by apelin-13.","journal":"Clinical and experimental pharmacology & physiology"},{"date":"2010 Nov 1","pmid":"21235436","title":"Cell biological manifestations of bisdioxopiperazines treatment of human tumor cell lines in culture.","journal":"Anti-cancer agents in medicinal chemistry"},{"date":"2010 Sep","pmid":"20950258","title":"Antimetastatic activities and mechanisms of bisdioxopiperazine compounds.","journal":"Anti-cancer agents in medicinal chemistry"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Razoxin is a small molecule with the synonyms ICI 59118, ICI-59118, ICRF 159, ICRF-159, NSC-129943, and RAZOXANE. It is being studied in clinical trials for various types of cancer, including Ewing's Sarcoma, Neuroblastoma, Rhabdomyosarcoma, Hepatoblastoma, Sarcoma, and Soft Tissue Sarcoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}